Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.63 |
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29415586 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29493550 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL2558967 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL15480253 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL8904188 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29415589 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL16401903 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL2558970 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL22283176 | 1.00 | CASP3 (0.63) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL23138547 | 0.94 | CASP3 (0.58) | CASP3MDM4TP53KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583857-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2026-03-24 | — | — | US | disclosed |
| EP-4673474-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-12377159-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4554623-A1 | ANTIBODY DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | Pheon Therapeutics Ltd (GB) | 2025-05-21 | — | — | EP | disclosed |
| CN-119836305-A | Antibody-drug conjugates | 费恩治疗有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119836306-A | Antibody drug conjugates that bind CDCP1 and uses thereof | 费恩治疗有限公司 | 2025-04-15 | — | — | CN | disclosed |
| EP-4525926-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| EP-4525925-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| US-20250011317-A1 | ANTI-PROLIFERATIVE AGENTS | PHEON THERAPEUTICS LTD (GB) | 2025-01-09 | — | — | US | disclosed |
| WO-2024182569-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-09-06 | — | — | WO | disclosed |
| US-20240101594-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2024-03-28 | — | — | US | disclosed |
| WO-2023225320-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225336-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| EP-4251209-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| EP-4251208-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| US-11760775-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. | 2023-09-19 | — | — | US | disclosed |
| WO-2022115451-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115477-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| EP-3972651-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972649-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101594-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | CASP3 4393/4885MDM4 3483/4885TP53 2530/4885 |
| US-12583857-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | CNR1, MTNR1B, MTNR1A | CASP3 1272/4885MDM4 4356/4885TP53 4135/4885 |
| US-20250011317-A1 | ANTI-PROLIFERATIVE AGENTS | CCND2, BRD2, CCND3 | CASP3 630/4885MDM4 1616/4885TP53 572/4885 |
| US-12377159-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | CASP3 4393/4885MDM4 3483/4885TP53 2530/4885 |
| US-11760775-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | CASP3 4393/4885MDM4 3483/4885TP53 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.